Cytosorbents Statistics
Total Valuation
Cytosorbents has a market cap or net worth of $72.50 million. The enterprise value is $96.11 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytosorbents has 62.50 million shares outstanding. The number of shares has increased by 21.90% in one year.
| Current Share Class | 62.50M |
| Shares Outstanding | 62.50M |
| Shares Change (YoY) | +21.90% |
| Shares Change (QoQ) | +0.48% |
| Owned by Insiders (%) | 12.61% |
| Owned by Institutions (%) | 26.88% |
| Float | 54.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.77 |
| Forward PS | 1.69 |
| PB Ratio | 5.73 |
| P/TBV Ratio | 9.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 2.42.
| Current Ratio | 2.20 |
| Quick Ratio | 1.08 |
| Debt / Equity | 2.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.00 |
Financial Efficiency
Return on equity (ROE) is -119.80% and return on invested capital (ROIC) is -26.30%.
| Return on Equity (ROE) | -119.80% |
| Return on Assets (ROA) | -20.91% |
| Return on Invested Capital (ROIC) | -26.30% |
| Return on Capital Employed (ROCE) | -44.71% |
| Revenue Per Employee | $238,889 |
| Profits Per Employee | -$139,053 |
| Employee Count | 149 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 3.43 |
Taxes
| Income Tax | -1.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.69% in the last 52 weeks. The beta is 1.17, so Cytosorbents's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | +29.69% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.05 |
| Relative Strength Index (RSI) | 66.62 |
| Average Volume (20 Days) | 71,004 |
Short Selling Information
The latest short interest is 1.75 million, so 2.79% of the outstanding shares have been sold short.
| Short Interest | 1.75M |
| Short Previous Month | 1.84M |
| Short % of Shares Out | 2.79% |
| Short % of Float | 3.20% |
| Short Ratio (days to cover) | 20.22 |
Income Statement
In the last 12 months, Cytosorbents had revenue of $35.59 million and -$20.72 million in losses. Loss per share was -$0.38.
| Revenue | 35.59M |
| Gross Profit | 25.13M |
| Operating Income | -16.79M |
| Pretax Income | -28.35M |
| Net Income | -20.72M |
| EBITDA | -15.22M |
| EBIT | -16.79M |
| Loss Per Share | -$0.38 |
Full Income StatementBalance Sheet
The company has $3.28 million in cash and $26.89 million in debt, giving a net cash position of -$23.61 million or -$0.38 per share.
| Cash & Cash Equivalents | 3.28M |
| Total Debt | 26.89M |
| Net Cash | -23.61M |
| Net Cash Per Share | -$0.38 |
| Equity (Book Value) | 11.11M |
| Book Value Per Share | 0.20 |
| Working Capital | 11.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.43 million and capital expenditures -$284,343, giving a free cash flow of -$14.71 million.
| Operating Cash Flow | -14.43M |
| Capital Expenditures | -284,343 |
| Free Cash Flow | -14.71M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
Gross margin is 70.59%, with operating and profit margins of -47.16% and -58.21%.
| Gross Margin | 70.59% |
| Operating Margin | -47.16% |
| Pretax Margin | -62.96% |
| Profit Margin | -58.21% |
| EBITDA Margin | -42.75% |
| EBIT Margin | -47.16% |
| FCF Margin | n/a |
Dividends & Yields
Cytosorbents does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.90% |
| Shareholder Yield | -21.90% |
| Earnings Yield | -28.58% |
| FCF Yield | -20.29% |
Analyst Forecast
The average price target for Cytosorbents is $4.67, which is 309.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.67 |
| Price Target Difference | 309.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 30.93% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 5, 2014. It was a reverse split with a ratio of 0.04:1.
| Last Split Date | Dec 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.04:1 |
Scores
Cytosorbents has an Altman Z-Score of -8.23 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.23 |
| Piotroski F-Score | 3 |